Skip to main content
Back
Watch Compare

Alaunos Therapeutics, Inc.

Data quality: 100%
TCRT
Nasdaq Manufacturing Chemicals
$2.89
▲ $0.04 (1.24%)
Mkt Cap: 6.37 M
Price
$2.86
Mkt Cap
6.37 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Revenue declined -66.52% annually over 5 years
Negative free cash flow of -2.97 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 16.52%
Capital intensive — 1960.00% of revenue goes to capex

Growth

Revenue Growth (5Y)
-66.52%
Below sector avg (1.82%)
Revenue (1Y)-50.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-129.21%
Below sector avg (-53.47%)
ROIC-103.27%
Net Margin-83520.00%
Op. Margin-84500.00%

Safety

Debt / Equity
N/A
Current Ratio2.92
Interest CoverageN/A

Valuation

PE (TTM)
-1.53
Below sector avg (-1.48)
P/B Ratio2.27
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -1.5 -1.5
P/B 2.3 1.6
ROE % -129.2 -53.5
Net Margin % -83520.0 -41.5
Rev Growth 5Y % -66.5 1.8
D/E — 0.3

Analyst Price Target

No analyst coverage available

Earnings Estimates

No forward estimates available

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42023 -$4.50 -$17.09 -279.9%
Q32023 -$5.25 -$4.41 +16.0%
Q22023 -$6.75 -$6.00 +11.1%
Q12023 -$6.60 -$6.00 +9.1%

All Fundamental Metrics
Growth
Revenue Growth (1Y) -50.00% Revenue Growth (3Y) 0.00%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -66.52% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 5,000.0 Net Income (TTM) -4.18 M
ROE -129.21% ROA -98.74%
Gross Margin N/A Operating Margin -84500.00%
Net Margin -83520.00% Free Cash Flow (TTM) -2.97 M
ROIC -103.27% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.92
Interest Coverage N/A Asset Turnover 0.00
Working Capital 1.76 M Tangible Book Value 2.80 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.53 Forward P/E N/A
P/B Ratio 2.27 P/S Ratio 1274.15
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -46.57%
Market Cap 6.37 M Enterprise Value 4.43 M
Per Share
EPS (Diluted TTM) -2.20 Revenue / Share 0.00
FCF / Share -1.33 OCF / Share -1.29
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1960.00% FCF Conversion 71.05%
SBC-Adj. FCF -3.60 M Growth Momentum 16.52

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 5,000.0 10,000.0 5,000.0 2.92 M 398,000.0
Net Income -4.18 M -4.68 M -35.14 M -37.73 M -78.75 M
EPS (Diluted) -2.20 -2.92 -2.20 -0.17 —
Gross Profit — — — — —
Operating Income -4.23 M -4.81 M -34.27 M -35.11 M -77.55 M
EBITDA — — — — —
R&D Expenses 1.36 M 362,000.0 16.28 M 25.02 M 49.64 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — 1.90 M 1.92 M 3.15 M 1.20 M
Income Tax 0.0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2.97 M 2.76 M 8.26 M 64.94 M 94.87 M
Total Liabilities 813,000.0 692,000.0 1.96 M 26.38 M 36.81 M
Shareholders' Equity 2.15 M 2.06 M 6.31 M 38.56 M 58.06 M
Total Debt — 0.0 0.0 0.0 16.25 M
Cash & Equivalents 1.39 M 1.09 M 6.06 M 39.06 M 76.05 M
Current Assets 1.99 M 2.76 M 8.26 M 53.80 M 78.83 M
Current Liabilities 813,000.0 692,000.0 1.96 M 24.17 M 16.04 M